The study’s goal was to summarize the experience of different Spanish hospitals using teduglutide in young patients with SBS (SBS). Teduglutide was given to seventeen juvenile patients who had intestinal failure as a result of SBS. Subcutaneous teduglutide was administered to patients at a rate of 0.05 mg kg1 day1. Patients’ demographics and changes in parenteral nutrition (PN) requirements, fecal losses, and citrulline levels were gathered at the start, 3, 6, and 12 months, as well as any adverse events. At baseline, patients were receiving an average of 55 ml kg1 day1 and 33 kcal kg1 day1 of parenteral supplementation. A total of 12/17 patients attained parenteral independence: 3 after 3 months, 4 after 6 months, and 5 after 12 months. One patient terminated treatment one year after it began because there were no improvements in parenteral support or fecal losses. Everyone else reduced their intravenous needs by half. One patient had cholecystitis, while another with pre-existing heart illness experienced cardiac decompensation.

Teduglutide appears to be a safe and effective therapy in the pediatric SBS population, outperforming both the pivotal study and the adult population.